| 2.52 -0.18 (-6.67%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.93 |
1-year : | 4.61 |
| Resists | First : | 3.37 |
Second : | 3.95 |
| Pivot price | 3.27 |
|||
| Supports | First : | 2.44 |
Second : | 2.03 |
| MAs | MA(5) : | 2.9 |
MA(20) : | 3.24 |
| MA(100) : | 2.91  |
MA(250) : | 3.97 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 4.5 |
D(3) : | 4.8 |
| RSI | RSI(14): 31.4 |
|||
| 52-week | High : | 9.13 | Low : | 1.37 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SERA ] has closed below the lower bollinger band by 6.5%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ SERA ] is to continue within current trading range. Bollinger Bands are 33.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.73 - 2.74 | 2.74 - 2.76 |
| Low: | 2.4 - 2.42 | 2.42 - 2.43 |
| Close: | 2.49 - 2.52 | 2.52 - 2.55 |
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Sun, 09 Nov 2025
Analyzing recovery setups for Sera Prognostics Inc. investors - Bond Market & AI Driven Stock Movement Reports - newser.com
Sun, 09 Nov 2025
Relative strength of Sera Prognostics Inc. in sector analysis - 2025 Market Outlook & Daily Profit Maximizing Trade Tips - newser.com
Sun, 09 Nov 2025
Analyzing recovery setups for Sera Prognostics Inc. investors - Quarterly Profit Review & Long-Term Capital Growth Strategies - newser.com
Thu, 06 Nov 2025
How to forecast Sera Prognostics Inc. trends using time series - Earnings Overview Summary & AI Driven Price Predictions - newser.com
Tue, 04 Nov 2025
Insider Sell: Robert Harrison Sells 2,000 Shares of Sera Prognos - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 2.443e+007 (%) |
| Held by Institutions | 10.9 (%) |
| Shares Short | 635 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.607e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -54 % |
| Return on Assets (ttm) | 823.5 % |
| Return on Equity (ttm) | -23.5 % |
| Qtrly Rev. Growth | 108000 % |
| Gross Profit (p.s.) | -30.11 |
| Sales Per Share | -45.61 |
| EBITDA (p.s.) | -18556.7 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.06 |
| Price to Cash Flow | 1.05 |
| Dividend | 0 |
| Forward Dividend | 532600 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|